Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate) vs Aniracetam

N/A

N/A

Published human studies used 400–600 mg/day for 2–12 weeks (cognitive/motivation trials) and single acute 600 mg doses (exercise study); the classic prescription dose (choline alfoscerate) in some markets is 1200 mg/day. These are reported as trial/regulatory facts, not recommendations. Alpha-GPC is a non-peptide small molecule sold as bulk powder or capsules at marketed purities of 50%, 99%, or 99.96%. No validated maximum safe dose, no controlled long-term safety data beyond 12 weeks, and no pediatric or pregnancy safety data were located.

Aniracetam is marketed in Greece as Referan (750 mg tablets and 1500 mg sachets) and in Italy as Ampamet/Draganon, representing real-world prescription doses in those jurisdictions, but no FDA-reviewed human dosing regimen exists. The compound exhibits very rapid and essentially complete GI absorption but undergoes extensive first-pass hepatic hydrolysis, yielding an absolute systemic bioavailability of the parent compound of only ~0.2% with a short half-life (~0.5 h); roughly 70% of the dose is converted to the active metabolite N-anisoyl-GABA. Independent laboratory testing of US nootropic supplements found aniracetam at 0.5–502 mg per serving versus a 200–750 mg pharmaceutical range, with 75% of products showing label-content mismatches. As a non-peptide small molecule, aniracetam does not require refrigeration.